AccurKardia, a medical AI software company based in New York, has raised $2.7 million in seed funding led by Popular Impact Fund. The company utilizes a combination of AI and non-AI techniques to deliver near-real-time ECG analytics through their cloud-based web application, native iOS app, and API. AccurKardia has also been selected to join Mayo Clinic Platform_Accelerate’s Cohort 3 program for access to resources and mentorship.
What You Should Know:
- AccurKardia, Inc., a New York-based medical AI software company delivering clinical-grade ECG interpretation software to cardiac monitoring companies raises $2.7M in seed funding led by Popular Impact Fund alongside other private investors.
- AccurKardia combines proprietary AI and non-AI-based techniques to provide near-real-time ECG analytics in the cloud, on device and at the edge
Clinical-grade, device-agnostic, API-accessible ECG analytics.
AccurKardia solutions include:
- AccurECG: cloud-based web application
- AccurBeat: native iOS app for the Apple Watch ECG
- AccurAPI: API that can be called directly from OEM software
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
In addition AccurKardia has been selected to join Cohort 3 of Mayo Clinic Platform_Accelerate a program that provides access to Mayo Clinic’s rich, de-identified data sets, validation frameworks, clinical workflow planning, and mentorship. Since March 2023, AccurKardia has been leveraging these assets to accelerate its R&D and clinical validation work.
Source: HitConsultant
